1. Prognostic value of baseline serum C-reactive protein level in intermediate risk group patients with metastatic renal cell carcinoma treated by first-line vascular endothelial growth factor targeted therapy
   Kimiharu Takamatsu et al, 2018, Clinical Genitourinary Cancer CrossRef
2. Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcino
   Jun Teishima et al, 2018, Int. J. Urol. CrossRef
3. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis
   Zhun Wang et al, 2017, Clinica Chimica Acta CrossRef
4. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival
   Jun Teishima et al, 2018, Urologic Oncology: Seminars and Original Investigations CrossRef
5. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
   Kosuke Ueda et al, 2018, Urol Oncol CrossRef
6. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
   Keiichi Ito et al, 2018 CrossRef
7. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
   Yoshihiko Tomita et al, 2019, BMC Cancer CrossRef
8. The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma
   Jun Teishima et al, 2016, BJU Int CrossRef
9. null
   Waliza Ansar et al, 2016 CrossRef
10. Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival
    Steffen Rausch et al, 2016, Int. J. Urol. CrossRef
11. Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib
    Tetsuo Fujita et al, 2017 CrossRef
12. Editorial Comment to C‐reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma
    Teruo Inamoto et al, 2019, Int. J. Urol. CrossRef
13. Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
    Nobuki Furubayashi et al, 2017 CrossRef
14. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
    Yosuke Yasuda et al, 2017, Int J Clin Oncol CrossRef
15. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
    Jun Teishima et al, 2017, Urologic Oncology: Seminars and Original Investigations CrossRef
16. Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma
    Ryuichi Mizuno et al, 2020, KCA CrossRef
17. C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
    Peter C. Hart et al, 2020, Front. Immunol. CrossRef
18. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor
    Kazuma Yukihiro et al, 2022, Urologic Oncology: Seminars and Original Investigations CrossRef
19. Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients
    Bruce Li et al, 2024 CrossRef